Stay updated with breaking news from Inborn Errors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to...
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
The absence of a protein that activates the body's antiviral defenses can cause a rare rheumatoid-like autoinflammatory condition that is treatable with an FDA-approved class of drugs known as TNF (tumor necrosis factor) inhibitors, a global research team led by Mount Sinai has found.
The absence of a protein that activates the body’s antiviral defenses can cause a rare rheumatoid-like autoinflammatory condition called TBK1, which is treatable with an existing FDA-approved drug.
Scientists found that a rare rheumatoid-like autoinflammatory condition that is treatable with a class of drugs known as TNF (tumor necrosis factor) inhibitors.